FAST platform for same-shift, complete antibiotic menu antibiotic susceptibility testing

此第一阶段SBIR提案的目标是展示对所有主要致病因素的效用 SeLux快速、低成本、表型抗生素敏感性试验的细菌菌株 (AST)系统(FAST-AST或FAST)。利用现有的光学探测器和标准干式 抗生素微孔板，以及避免代谢探针的陷阱，FAST将有可能转变 通过显著加速AST来治疗感染，从而促进用 最佳抗生素。目标1将快速应用于数百个致病细菌菌株的样本， 同时开发和优化用于临床实用的预测算法。AIM 2将延长 快速平台也是生长缓慢的菌株和物种的平台。SeLux已经展示了快速 超过FDA 510(K)对25+最低抑菌浓度测定的要求 带有完整抗生素板的金黄色葡萄球菌和大肠杆菌菌株。完成 拟议的目标将迅速扩展到所有与临床相关的、非挑剔的主要细菌。 病原体。SeLux的跨学科团队在纳米传感、微生物学和 算法设计，并得到了临床微生物学、感染性疾病的杰出专家的支持 疾病和机器学习。

The goal of this Phase I SBIR proposal is to demonstrate utility to all major pathogenic bacterial strains of SeLux’s rapid, low-cost, phenotypic antibiotic susceptibility test (AST) system (fast-AST or FAST). Utilizing existing optical detectors and standard dried antibiotic microplates, and avoiding pitfalls of metabolic probes, FAST will potentially transform therapy of infections by significantly accelerating AST, thereby facilitating treatment with the optimal antibiotic. Aim 1 will apply FAST to hundreds of samples of pathogenic bacterial strains, while developing and optimizing a predictive algorithm for clinical utility. Aim 2 will extend the FAST platform to slow-growing strains and species as well. SeLux has demonstrated FAST to exceed FDA 510(k) requirements for minimum inhibitory concentration determinations for 25+ strains of Staphylococcus aureus and Escherichia coli with full antibiotic panels. Completion of the proposed aims will expand FAST to all major clinically-relevant, non-fastidious bacterial pathogens. SeLux’s interdisciplinary team has expertise in nanosensing, microbiology, and algorithm design and is buttressed by distinguished experts in Clinical Microbiology, Infectious Disease, and Machine Learning.